Medication: Difference between revisions
No edit summary |
No edit summary |
||
| Line 323: | Line 323: | ||
<!--T:96--> | <!--T:96--> | ||
In the UK, the Pharmaceutical Price Regulation Scheme is intended to ensure that the [[National Health Service|National Health Service]] is able to purchase drugs at reasonable prices. The prices are negotiated between the Department of Health, acting with the authority of Northern Ireland and the UK Government, and the representatives of the Pharmaceutical industry brands, the [[Association of the British Pharmaceutical Industry|Association of the British Pharmaceutical Industry]] (ABPI). For 2017 this payment percentage set by the PPRS will be 4,75%. | In the UK, the Pharmaceutical Price Regulation Scheme is intended to ensure that the [[:en:National Health Service|National Health Service]] is able to purchase drugs at reasonable prices. The prices are negotiated between the Department of Health, acting with the authority of Northern Ireland and the UK Government, and the representatives of the Pharmaceutical industry brands, the [[:en:Association of the British Pharmaceutical Industry|Association of the British Pharmaceutical Industry]] (ABPI). For 2017 this payment percentage set by the PPRS will be 4,75%. | ||
===Canada=== <!--T:97--> | ===Canada=== <!--T:97--> | ||